ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,252Medicare Part D Prescriptions Filled, Including Refills

Rank: 132 out of 973

$553K Total Retail Price of All Prescriptions

Rank: 102 out of 973

593 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
21% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Kansas
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 593 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

13% of this provider’s 593 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 9,054 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Kansas
SIMVASTATIN 654 611 1 1
LEVOTHYROXINE SODIUM 396 352 2 2
AMLODIPINE BESYLATE 391 366 3 7
OMEPRAZOLE 328 284 4 5
HYDROCODONE-ACETAMINOPHEN 283 237 S3 5 4
HYDROCHLOROTHIAZIDE 282 269 6 11
FUROSEMIDE 242 221 7 6
ATORVASTATIN CALCIUM 230 205 8 15
LISINOPRIL 228 214 9 3
POTASSIUM CHLORIDE 211 176 10 9
WARFARIN SODIUM 209 188 11 10
METFORMIN HCL 208 164 12 8
ALENDRONATE SODIUM 189 185 13 24
GABAPENTIN 187 154 14 12
ATENOLOL 147 125 15 16
ZOLPIDEM TARTRATE 133 109 16 20
CITALOPRAM HBR 122 116 17 14
FENOFIBRATE 121 114 18 77
NAMENDA 112 112 19 31
CRESTOR 110 78 20 34
SERTRALINE HCL 107 102 21 21
METOPROLOL TARTRATE 106 101 22 13
GLIMEPIRIDE 102 91 23 41
PROAIR HFA 99 73 24 54
DONEPEZIL HCL 96 96 25 26
TRAMADOL HCL 96 92 25 18
LANTUS 95 74 27 39
FLUOXETINE HCL 95 86 27 56
LOSARTAN POTASSIUM 90 76 29 19
PREDNISONE 88 81 30 33
LISINOPRIL-HYDROCHLOROTHIAZIDE 87 75 31 25
METFORMIN HCL ER 79 71 32 58
NEXIUM 72 49 33 30
TAMSULOSIN HCL 72 72 33 28
PRAVASTATIN SODIUM 71 68 35 22
SYNTHROID 68 64 36 50
NOVOLOG 64 36 37 82
OXYBUTYNIN CHLORIDE 59 36 38 92
FLUTICASONE PROPIONATE 56 54 39 35
INSULIN SYRINGE 56 42 39 153
LOVASTATIN 54 53 41 38
TRICOR 54 52 41 143
METOPROLOL SUCCINATE 51 39 43 17
BUSPIRONE HCL 50 43 44 98
CYCLOBENZAPRINE HCL 50 46 R 44 42
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 23, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.